Geneva, Sept. 21 -- International Clinical Trials Registry received information related to the study (NCT07814976) titled 'Hyoscine Butylbromide During Transcystic Papillary Balloon Dilation for Choledocholithiasis' on Sept. 4.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: Riga East Clinical University Hospital
Condition:
Choledocholithiasis
Common Bile Duct Stones
Intervention:
Drug: Hyoscine Butylbromide
Recruitment Status: Recruiting
Phase: N/A
Date of First Enrollment: January 4, 2026
Target Sample Size: 50
Countries of Recruitment:
Latvia
To know more, visit https://clinicaltrials.gov/stu...